Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
We highlight some ETF areas that held their ground and gained popularity among investors amid the coronavirus crisis.
The Nasdaq clocked double-digit gains for two years in a row in 2020. It may log double-digit gains in 2021 all over again if the virus scenario does not improve as fast as expected.
Sector ETF report for PBE
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The annual...
Here we highlight some ETFs that can help investors make the most of the favorable investing opportunities amid the coronavirus crisis.
, /PRNewswire/ --Â Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will...
, /PRNewswire/ --Â (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases,...
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
Sector ETF report for PBE
Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
